

Hepatic safety of ketoconazole in Cushing's syndrome Programme in France

European Journal of Endocrinology

178, 447-458

DOI: [10.1530/eje-17-0886](https://doi.org/10.1530/eje-17-0886)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study. <i>Frontiers in Endocrinology</i> , 2019, 10, 436.	1.5	13
3	Functioning Pituitary Adenomas – Current Treatment Options and Emerging Medical Therapies. <i>European Endocrinology</i> , 2019, 15, 30.	0.8	42
4	Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2019, 7, 855-865.	5.5	60
5	Medical Management of Cushing's Syndrome: Current and Emerging Treatments. <i>Drugs</i> , 2019, 79, 935-956.	4.9	39
6	Les traitements du syndrome de Cushing. <i>Actualites Pharmaceutiques</i> , 2019, 58, 33-37.	0.0	0
7	Therapeutic options after surgical failure in Cushing's disease: A critical review. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2019, 33, 101270.	2.2	20
8	Fluconazole as a New Therapeutic Tool to Manage Patients With NPT1c (SLC34A3) Mutation: A Case Report. <i>American Journal of Kidney Diseases</i> , 2019, 73, 886-889.	2.1	14
9	The sinister side of Cushing's therapy. <i>Lancet Diabetes and Endocrinology</i> , the, 2019, 7, 822-823.	5.5	0
10	Drug design strategies for Cushing's syndrome. <i>Expert Opinion on Drug Discovery</i> , 2019, 14, 143-151.	2.5	3
11	Updates in the Medical Treatment of Pituitary Adenomas. <i>Hormone and Metabolic Research</i> , 2020, 52, 8-24.	0.7	21
12	Management of patients with persistent or recurrent Cushing's disease after initial pituitary surgery. <i>Expert Review of Endocrinology and Metabolism</i> , 2020, 15, 321-339.	1.2	16
13	Managing common endocrine disorders amid COVID-19 pandemic. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 767-771.	1.8	29
14	Adrenally Directed Medical Therapies for Cushing Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 16-25.	1.8	28
15	Persistent Cushing's Disease after Transsphenoidal Surgery: Challenges and Solutions. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021, 129, 208-215.	0.6	5
16	Ketoconazole in Cushing's syndrome: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2021, 37, 55-64.	0.3	13
17	Approach to the Patient Treated with Steroidogenesis Inhibitors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2114-2123.	1.8	39
18	Osilodrostat for the treatment of Cushing's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1099-1106.	0.9	6
19	Drug Repurposing Patent Applications July – September 2020. <i>Assay and Drug Development Technologies</i> , 2021, 19, 204-208.	0.6	0

#	ARTICLE	IF	CITATIONS
20	COVID-19 and the Endocrine System: A Comprehensive Review on the Theme. Journal of Clinical Medicine, 2021, 10, 2920.	1.0	57
21	Levoketoconazole: a novel treatment for endogenous Cushing's syndrome. Expert Review of Endocrinology and Metabolism, 2021, 16, 159-174.	1.2	8
22	Effectiveness of Medical Treatment of Cushing's Disease: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology, 2021, 12, 732240.	1.5	13
23	Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome " A practical guide. Best Practice and Research in Clinical Endocrinology and Metabolism, 2021, 35, 101490.	2.2	23
24	Should we avoid using ketoconazole in patients with severe Cushing's syndrome and increased levels of liver enzymes?. European Journal of Endocrinology, 2018, 179, L1-L2.	1.9	13
25	MANAGEMENT OF ENDOCRINE DISEASE: Cushing's syndrome due to ectopic ACTH secretion: an expert operational opinion. European Journal of Endocrinology, 2020, 182, R29-R58.	1.9	120
26	ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of Cushing's syndrome. European Journal of Endocrinology, 2020, 183, G1-G7.	1.9	61
27	Treatment of Cushing's Syndrome : What Place for Medical Treatment?. Acta Endocrinologica, 2019, 15, 237-243.	0.1	7
28	Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes and Endocrinology, the, 2021, 9, 847-875.	5.5	315
29	Cushing's disease. Presse Medicale, 2021, 50, 104091.	0.8	7
30	Current and Emerging Medical Therapies in Pituitary Tumors. Journal of Clinical Medicine, 2022, 11, 955.	1.0	7
31	How the diagnosis and the management of genetic renal phosphate leak impact the life of kidney stone formers?. Urolithiasis, 2022, , 1.	1.2	0
33	The Mount Sinai Clinical Pathway for the Diagnosis and Management of Hypercortisolism due to Ectopic ACTH Syndrome. Journal of the Endocrine Society, 2022, 6, .	0.1	8
34	Fluconazole in hypercalciuric patients with increased 1,25(OH)2D levels: the prospective, randomized, placebo-controlled, double-blind FLUCOLITH trial. Trials, 2022, 23, .	0.7	1
35	How best to monitor the specific side effects of medical treatments of Cushing's disease. Best Practice and Research in Clinical Endocrinology and Metabolism, 2022, 36, 101718.	2.2	3
36	Recurrent Neuroendocrine Tumor of the Cervix Presenting With Ectopic Cushing's Syndrome. Cureus, 2022, , .	0.2	0
37	Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France. Journal of Clinical Endocrinology and Metabolism, 2023, 108, 1475-1487.	1.8	11
38	Medical treatment of Cushing's disease with concurrent diabetes mellitus. Frontiers in Endocrinology, 0, 14, .	1.5	2

#	ARTICLE	IF	CITATIONS
39	An evaluation of pharmacological options for Cushing's disease: what are the state-of-the-art options?. Expert Opinion on Pharmacotherapy, 2023, 24, 557-576.	0.9	1
41	An individualized approach to the management of Cushing disease. Nature Reviews Endocrinology, 2023, 19, 581-599.	4.3	2